AR007098A1 - Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas - Google Patents
Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticasInfo
- Publication number
- AR007098A1 AR007098A1 ARP970101978A ARP970101978A AR007098A1 AR 007098 A1 AR007098 A1 AR 007098A1 AR P970101978 A ARP970101978 A AR P970101978A AR P970101978 A ARP970101978 A AR P970101978A AR 007098 A1 AR007098 A1 AR 007098A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- compounds
- compositions
- prepare pharmaceutical
- disorders
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 102000005741 Metalloproteases Human genes 0.000 abstract 2
- 108010006035 Metalloproteases Proteins 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010053177 Epidermolysis Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 208000002528 coronary thrombosis Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se presentan compuestos inhibitorios de la metaloproteasa de matriz, que tienen la fórmula (I), donde r es 0-2, T es seleccionada entre las fórmulas(II) y R40 es una estructura mono- o bi-heterocíclica como se ha definido en la memoriadescript iva. Estos compuestos son útiles para inhibir lasmetaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritisreumatoidea, la artritis séptica, lasenfermedades pe riodontales, las úlceras de córnea, la proteinuria, la enfermedad de aneurisma aórtico, laepidermólisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osteopenias en las que media laactividad de MMP, l aenfermedad de la articulación temporomandibular, las enfermedades desmielinizantes del sistema nervioso; las metástasis de tumores o la pérdidadegenerativa de cartílago posterior a la lesión articular traumática, yla trombosis co ronaria por ruptura de placa ateoesclerótica. Presenta asimismocomposiciones farmacéuticas y uso de dichos compuestos para preparar composicioanes farmacéuticas que los contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64849396A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007098A1 true AR007098A1 (es) | 1999-10-13 |
Family
ID=24601014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101978A AR007098A1 (es) | 1996-05-15 | 1997-05-12 | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0923530B1 (es) |
| JP (1) | JP3354942B2 (es) |
| CN (1) | CN1100748C (es) |
| AR (1) | AR007098A1 (es) |
| AT (1) | ATE275123T1 (es) |
| AU (1) | AU714207B2 (es) |
| BR (1) | BR9709086A (es) |
| CA (1) | CA2254731C (es) |
| CO (1) | CO5011061A1 (es) |
| DE (1) | DE69730508T2 (es) |
| DK (1) | DK0923530T3 (es) |
| ES (1) | ES2227696T3 (es) |
| HR (1) | HRP970244B1 (es) |
| ID (1) | ID17291A (es) |
| MY (1) | MY132463A (es) |
| PA (1) | PA8429701A1 (es) |
| PE (1) | PE66898A1 (es) |
| PT (1) | PT923530E (es) |
| SV (1) | SV1997000036A (es) |
| TN (1) | TNSN97083A1 (es) |
| TW (1) | TW539672B (es) |
| WO (1) | WO1997043239A1 (es) |
| YU (1) | YU18597A (es) |
| ZA (1) | ZA974030B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925637A (en) * | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| GB9922710D0 (en) * | 1999-09-24 | 1999-11-24 | Bayer Ag | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| JP2004359546A (ja) * | 2001-03-15 | 2004-12-24 | Ono Pharmaceut Co Ltd | ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤 |
| US20050119305A1 (en) * | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
| KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| AU2009283195A1 (en) * | 2008-08-18 | 2010-02-25 | Yale University | MIF modulators |
| JP2017509665A (ja) * | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類 |
| US20170022171A1 (en) | 2014-04-03 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentanecarboxylic acids and their use |
| US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
| CN113979992B (zh) * | 2021-11-19 | 2022-06-24 | 西安欧得光电材料有限公司 | 一种3-取代二苯并噻吩及其合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3827324B2 (ja) * | 1994-01-22 | 2006-09-27 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
| ATE214368T1 (de) | 1995-12-22 | 2002-03-15 | Warner Lambert Co | Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase |
| CO5011071A1 (es) | 1996-05-15 | 2001-02-28 | Bayer Corp | Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen |
-
1997
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en not_active Ceased
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2254731A1 (en) | 1997-11-20 |
| DE69730508D1 (de) | 2004-10-07 |
| PE66898A1 (es) | 1998-10-22 |
| ES2227696T3 (es) | 2005-04-01 |
| HK1021897A1 (en) | 2000-07-14 |
| CN1100748C (zh) | 2003-02-05 |
| BR9709086A (pt) | 1999-08-03 |
| MY132463A (en) | 2007-10-31 |
| DK0923530T3 (da) | 2005-01-03 |
| DE69730508T2 (de) | 2005-09-29 |
| EP0923530A1 (en) | 1999-06-23 |
| JP3354942B2 (ja) | 2002-12-09 |
| JPH11510821A (ja) | 1999-09-21 |
| CA2254731C (en) | 2004-07-20 |
| HRP970244A2 (en) | 1998-04-30 |
| ID17291A (id) | 1997-12-18 |
| PT923530E (pt) | 2004-12-31 |
| AU714207B2 (en) | 1999-12-23 |
| HRP970244B1 (en) | 2005-06-30 |
| YU18597A (sh) | 2001-12-26 |
| ATE275123T1 (de) | 2004-09-15 |
| PA8429701A1 (es) | 2000-05-24 |
| TW539672B (en) | 2003-07-01 |
| WO1997043239A1 (en) | 1997-11-20 |
| ZA974030B (en) | 1998-02-19 |
| SV1997000036A (es) | 1998-07-20 |
| CN1225621A (zh) | 1999-08-11 |
| AU3122097A (en) | 1997-12-05 |
| TNSN97083A1 (fr) | 2005-03-15 |
| CO5011061A1 (es) | 2001-02-28 |
| EP0923530B1 (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas | |
| ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| TNSN99156A1 (fr) | Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| AR002718A1 (es) | Acidos hidroxamicos que contienen lactamas y composicion farmaceutica con los mismos. | |
| HN1997000067A (es) | Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz | |
| BR9713186A (pt) | Inibidores de metaloprotease 1,3-diheterocìclicos | |
| PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| TNSN98036A1 (fr) | Derives d'acide hexanoique nouveaux | |
| AR004671A1 (es) | Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen | |
| NO20000784L (no) | Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt | |
| TNSN99111A1 (fr) | Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN99013A1 (fr) | Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98185A1 (fr) | Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TR199900945T2 (xx) | Matriks metaloproteaz �nleyiciler olarak ikameli 4-bifenil-4-hidroksib�tirik asit t�revleri. | |
| TR200003252T2 (tr) | Interleukın-1ß dönüştürme enzimi succınamıde inhibitörleri. | |
| AR007100A1 (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento. | |
| YU18397A (en) | MATRIX METALLOPROTEASES INHIBITING COMPOUND, 2(ω-ARYOYL-ALKYL)-4-BIARYL-4-OXOBUTYRIC ACID | |
| AR007097A1 (es) | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. | |
| PE23396A1 (es) | Benzotiofeno de glucopiranosido | |
| AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
| UY26079A1 (es) | Nuevos derivados de morfolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ECSP972113A (es) | Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos | |
| DK1246825T3 (da) | Kondenserede pyrrolforbindelser, farmaceutiske midler indeholdende dem og anvendelse deraf | |
| ECSP972112A (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenetilo sustituido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |